Virios Therapeutics (VIRI) Competitors $4.86 +0.01 (+0.21%) As of 08/4/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. TNXP, AURA, PRTA, CADL, GLUE, RNAC, FHTX, RCKT, INBX, and ABEOShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Tonix Pharmaceuticals (TNXP), Aura Biosciences (AURA), Prothena (PRTA), Candel Therapeutics (CADL), Monte Rosa Therapeutics (GLUE), Cartesian Therapeutics (RNAC), Foghorn Therapeutics (FHTX), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), and Abeona Therapeutics (ABEO). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Its Competitors Tonix Pharmaceuticals Aura Biosciences Prothena Candel Therapeutics Monte Rosa Therapeutics Cartesian Therapeutics Foghorn Therapeutics Rocket Pharmaceuticals Inhibrx Biosciences Abeona Therapeutics Tonix Pharmaceuticals (NASDAQ:TNXP) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Do institutionals and insiders believe in TNXP or VIRI? 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor TNXP or VIRI? In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Virios Therapeutics. MarketBeat recorded 5 mentions for Tonix Pharmaceuticals and 0 mentions for Virios Therapeutics. Tonix Pharmaceuticals' average media sentiment score of 0.86 beat Virios Therapeutics' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Tonix Pharmaceuticals Positive Virios Therapeutics Neutral Do analysts rate TNXP or VIRI? Tonix Pharmaceuticals currently has a consensus target price of $70.00, indicating a potential upside of 46.75%. Virios Therapeutics has a consensus target price of $5.00, indicating a potential upside of 2.88%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Tonix Pharmaceuticals is more favorable than Virios Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is TNXP or VIRI more profitable? Virios Therapeutics has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,313.87%. Tonix Pharmaceuticals' return on equity of -120.96% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,313.87% -120.96% -101.28% Virios Therapeutics N/A -130.33%-115.00% Which has more volatility and risk, TNXP or VIRI? Tonix Pharmaceuticals has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Which has better earnings and valuation, TNXP or VIRI? Virios Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Virios Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M34.79-$130.04M-$1.96 thousand-0.02Virios TherapeuticsN/AN/A-$5.30M-$0.27-18.00 SummaryTonix Pharmaceuticals beats Virios Therapeutics on 11 of the 15 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.59M$786.69M$5.59B$9.54BDividend YieldN/A4.84%4.73%4.13%P/E Ratio-18.001.0919.1622.30Price / SalesN/A25.05445.9598.89Price / CashN/A19.5635.6858.35Price / Book24.306.478.165.60Net Income-$5.30M-$4.35M$3.25B$265.26M7 Day Performance0.83%-4.86%0.45%-1.00%1 Month Performance1.25%-0.82%8.27%6.09%1 Year Performance2,501.71%19.62%30.29%23.81% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$4.86+0.2%$5.00+2.9%+2,466.1%$93.59MN/A-18.005Upcoming EarningsTNXPTonix Pharmaceuticals3.3301 of 5 stars$47.30-4.9%$70.00+48.0%-6.9%$365.84M$10.09M-0.0250AURAAura Biosciences2.1042 of 5 stars$6.99-3.3%$22.00+214.7%-28.5%$363.44MN/A-3.6850News CoveragePositive NewsPRTAProthena3.1069 of 5 stars$6.87+2.8%$31.50+358.5%-67.2%$359.56M$135.16M-3.30130News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastCADLCandel Therapeutics2.2982 of 5 stars$6.86-2.3%$22.00+220.7%+16.6%$351.72M$120K-5.1260News CoverageUpcoming EarningsGLUEMonte Rosa Therapeutics1.2665 of 5 stars$5.55-2.1%$15.33+176.3%+21.7%$348.76M$75.62M69.3890RNACCartesian Therapeutics2.0485 of 5 stars$13.70+2.8%$40.00+192.0%-13.3%$345.97M$38.91M-0.2664News CoveragePositive NewsUpcoming EarningsFHTXFoghorn Therapeutics3.2149 of 5 stars$6.50+5.0%$12.13+86.5%-16.0%$345.04M$23.50M-4.78120News CoverageEarnings ReportUpcoming EarningsRCKTRocket Pharmaceuticals4.851 of 5 stars$3.11-1.0%$17.87+474.5%-85.3%$335.31MN/A-1.18240Trending NewsINBXInhibrx Biosciences1.1454 of 5 stars$24.57+6.5%N/A+53.2%$334.11M$200K0.21166News CoverageUpcoming EarningsABEOAbeona Therapeutics3.8677 of 5 stars$6.62+1.4%$19.25+190.8%+36.6%$334.05M$3.50M-5.2190Upcoming Earnings Related Companies and Tools Related Companies Tonix Pharmaceuticals Alternatives Aura Biosciences Alternatives Prothena Alternatives Candel Therapeutics Alternatives Monte Rosa Therapeutics Alternatives Cartesian Therapeutics Alternatives Foghorn Therapeutics Alternatives Rocket Pharmaceuticals Alternatives Inhibrx Biosciences Alternatives Abeona Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIRI Stock Alerts